Product
Zemaira
1 clinical trial
2 indications
Indication
Alpha-1 Antitrypsin DeficiencyClinical trial
Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of INBRX-101 Compared to Plasma-Derived Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults With Alpha-1 Antitrypsin Deficiency (AATD) EmphysemaStatus: Recruiting, Estimated PCD: 2025-05-01